Connect with us

Newsletters

The Capitalist Newsletter – March 24, 2017

Published

on

GOP LEADERS POSTPONE VOTE ON HEALTHCARE REFORM; TRUMP LOSING HIS GRIP ON THE PARTY?


Donald Trump’s two biggest during his election were a border wall which Mexico would pay for and the immediate repeal and replacement of the Affordable Care Act. And while Trump has pushed for both, neither seems likely to happen anytime soon. The wall hasn’t been approved by lawmakers, but Trump and Customs and Border Patrol have started accepting bids to build it. Trumpcare, on the other hand, isn’t looking nearly as healthy. Is Trump losing his already tenuous grip on the majority party?

Read The Capitalist’s Take Here

Read More at NY Times

Read More at LA Times


DISNEY INKS IGER TO JULY 2019

As many expected, Robert Iger will stay on a while longer as Disney’s CEO and Chairman. The Walt Disney Company board said Thursday that it had extended Iger’s contract to July 2, 2019. The board cited Iger’s “outstanding leadership, his record of success in a changing media landscape, and his clear strategic vision for Disney’s future.” Iger, who is 66, had previously set a target departure date of 2018; his previous contract ran into mid-2018. But last April, one of the leading candidates to succeed Iger, Disney COO Thomas Staggs, stepped down.

Read More at USA Today Here

Read More at The Street Here

Read More at LA Times Here

Raven_Steel_Ad-04
Raven_Steel_Ad-05

THERANOS FOUNDER TO GIVE UP SHARES TO INVESTORS WHO PLEDGE NOT TO SUE

Theranos Inc. plans to give additional shares to investors who pledge not to sue the battered blood-testing company or Elizabeth Holmes, its founder and chief executive, people familiar with the matter said. The deal includes investors who participated in Theranos’s latest funding rounds, which ended in 2015 and brought in more than $600 million. Those investors could get about two additional shares for each share they bought, one of the people said. The additional shares would come from Holmes’s personal stake in Theranos, some of the people said. That would result in her relinquishing her majority ownership of the closely held Palo Alto, Calif., company, some of the people said…

Read More at MarketWatch

Read More at TechCrunch Here

Read More at Wall Street Journal Here


Closing Bell

– Thursday, March 23rd

Markets Tick DOWN as Healthcare Vote Postponed

Big Insider Trades

– Vonage Holdings Corp. (VG) Director Jeffrey Citron Sells $2.65m

– Intrepid Potash, Inc. (IPI) Director Landis Martin Buys $3.75m

Winners & Losers

– HTG Molecular Diagnostics, Inc. (HTGM) Soars UP (83.64%) After Obtaining CE Marking from the European Union for its Vitro Diagnostic Assay

– Alphatec Holdings, Inc. (ATEC) Slips DOWN (22.76%) After Securing $18.9m Private Placement

Most Talked About

Flexion Therapeutics, Inc. (FLXN) Considered a Majority Strong Buy on Rumors the Company is About to Accept a Takeover Bid

The TIP Sheets

– Thursday, March 23rd

– Cancer Genetics, Inc. (CGIX) Rises UP (15.52%) After Announcing Record Revenue for Q4 and Full Year 2016. The Company also Provided a Rosy Outlook for 2017. Expect Shares to Continue UP

Unusual Volume

HTG Molecular Diagnostics, Inc. (HTGM) Rockets UP (83.64%) on 44m Shares Traded After Obtaining CE Marking from the European Union for its Vitro Diagnostic Assay. The CE Marking is a Legal Requirement for Medical Equipment Ensuring Users the Equipment Works as Promised. Expect Shares to Continue UP

Click to comment

Leave a Reply

Your email address will not be published.

Continue Reading

Subscribe To Our Newsletter:



Copyright © 2020 The Capitalist. his copyrighted material may not be republished without express permission. The information presented here is for general educational purposes only. MATERIAL CONNECTION DISCLOSURE: You should assume that this website has an affiliate relationship and/or another material connection to the persons or businesses mentioned in or linked to from this page and may receive commissions from purchases you make on subsequent web sites. You should not rely solely on information contained in this email to evaluate the product or service being endorsed. Always exercise due diligence before purchasing any product or service. This website contains advertisements.

[email]
[email]